BioScience Health Innovations I
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $750.9K | $1.6M | $1.1M | $1.8M | $1.2M | $610.2K | $573.0K |
| Cost of Revenue | $376.9K | $265.4K | $1.0M | $433.2K | $683.0K | $330.9K | $271.2K | $148.2K |
| Gross Profit | $659.5K | $485.6K | $571.9K | $698.2K | $1.1M | $896.1K | $339.0K | $424.7K |
| Gross Margin | 63.6% | 64.7% | 36.4% | 61.7% | 61.1% | 73.0% | 55.6% | 74.1% |
| Operating Expenses | ||||||||
| Research & Development | — | $49.7K | — | — | — | $37.5K | — | — |
| SG&A Expense | $804.1K | $625.8K | $656.2K | $576.7K | $540.1K | $433.6K | $300.2K | $345.3K |
| Operating Income | $-217.9K | $-229.9K | $-156.7K | $-8.8K | $457.7K | $426.8K | $10.0K | $56.2K |
| Operating Margin | -21.0% | -30.6% | -10.0% | -0.8% | 26.0% | 34.8% | 1.6% | 9.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $-32.1K | — | — | — | $0 | — | — | $0 |
| Net Income | $-185.8K | $-229.9K | $-233.6K | $-8.8K | $457.7K | $426.8K | $10.0K | $56.2K |
| Net Margin | -17.9% | -30.6% | -14.9% | -0.8% | 26.0% | 34.8% | 1.6% | 9.8% |
| EPS (Basic) | $-0.02 | $-0.02 | $0.01 | $0.00 | $0.04 | $0.01 | $0.00 | $0.01 |
| EPS (Diluted) | $-0.02 | $-0.02 | $0.01 | $0.00 | $0.04 | $0.01 | $0.00 | $0.01 |
| Shares Outstanding (Basic) | 11.7M | 11.4M | 11.0M | 11.0M | 11.0M | 43.9M | 10.5M | 10.5M |
| Shares Outstanding (Diluted) | 11.7M | 11.4M | 11.4M | 11.0M | 11.4M | 44.3M | 10.9M | 10.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |